Pixium Vision S.A. (PXMVF) Research

Pixium Vision S.A., established in Paris, France, in 2011, is a pioneering firm specializing in bioelectronics and brain-machine interface technologies, with a particular emphasis on neuromodulation. The company's flagship product is the PRIMA System, an advanced bionic vision solution designed to restore sight for individuals experiencing profound vision impairment. This often includes patients with retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD), as well as other conditions leading to blindness. The PRIMA System functions by circumventing the damaged natural photoreceptor cells and instead electrically stimulating the inner retina's nerve cells, which then convey visual data via the optic nerve directly to the brain. Pixium Vision S.A. actively collaborates with a network of distinguished institutions, including Stanford University, the Institut de la Vision, Moorfields Eye Hospital, the Institute of Ocular Microsurgery, University Hospital, and UPMC.

Open Pixium Vision S.A. (PXMVF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.